Published in J Clin Endocrinol Metab on July 12, 2012
Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) (DMAU) | NCT02927210
Contraception technology: past, present and future. Contraception (2012) 1.06
Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels. Andrology (2013) 0.85
Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception (2014) 0.81
Male hormonal contraception: hope and promise. Lancet Diabetes Endocrinol (2016) 0.78
Male Hormonal Contraception: Where Are We Now? Curr Obstet Gynecol Rep (2016) 0.78
Advances in male hormonal contraception. Indian J Med Res (2014) 0.78
Male hormonal contraception: looking back and moving forward. Andrology (2015) 0.76
Male contraception. Best Pract Res Clin Obstet Gynaecol (2014) 0.76
Recombinant production of enzymatically active male contraceptive drug target hTSSK2 - Localization of the TSKS domain phosphorylated by TSSK2. Protein Expr Purif (2016) 0.76
Male contraception. Fertil Steril (2016) 0.75
Pipeline for contraceptive development. Fertil Steril (2016) 0.75
Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France. Basic Clin Androl (2017) 0.75
Effective Delivery of Male Contraceptives Behind the Blood-Testis Barrier (BTB) - Lesson from Adjudin. Curr Med Chem (2016) 0.75
Male fertility: Is spermiogenesis the critical step for answering biomedical issues? Spermatogenesis (2013) 0.75
Beyond the Condom: Frontiers in Male Contraception. Semin Reprod Med (2016) 0.75
Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet (1990) 2.73
Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab (2009) 2.37
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab (2004) 2.35
Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth. Contraception (2008) 2.31
A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab (2003) 2.03
Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab (2000) 1.99
Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril (1996) 1.79
Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab (2008) 1.79
Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod (2000) 1.31
Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab (2003) 1.26
Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod (2004) 1.23
A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl (2003) 1.19
Optimal power transformations for analysis of sperm concentration and other semen variables. J Androl (2002) 1.15
Would women trust their partners to use a male pill? Hum Reprod (2000) 1.12
Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. Clin Chem (2008) 1.11
Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab (2006) 1.05
Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab (1996) 1.05
Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab (2008) 1.05
Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl (2006) 1.00
Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. J Clin Endocrinol Metab (2004) 1.00
Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab (2005) 1.00
Does ethnicity matter in male hormonal contraceptive efficacy? Asian J Androl (2011) 0.96
The use of newer progestins for contraception. Contraception (2010) 0.94
Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab (2009) 0.93
10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. October 22-23, 2006. Contraception (2007) 0.91
A review of androgen-progestin regimens for male contraception. J Androl (2003) 0.90
Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab (2001) 0.90
Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab (2002) 0.89
Male hormonal contraception. Am J Obstet Gynecol (2004) 0.87
Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol (Oxf) (2000) 0.87
Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men. J Clin Endocrinol Metab (2005) 0.87
Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab (1999) 0.84
Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab (1996) 0.84
A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab (2001) 0.84
Use of progestins in male contraception. Steroids (2003) 0.82
Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev (2007) 0.81
Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril (1989) 0.79
Serum lipids, blood pressure, body weight, and serum chemistry in women using subcutaneous contraceptive implants releasing the progestin ST 1435. Obstet Gynecol (1992) 0.77
Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435. Contraception (1981) 0.77
World Health Organization reference values for human semen characteristics. Hum Reprod Update (2009) 7.71
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2010) 7.15
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2006) 5.58
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet (2010) 4.59
Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab (2002) 4.46
Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab (2004) 3.45
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab (2004) 3.02
Acute secondary adrenal insufficiency after traumatic brain injury: a prospective study. Crit Care Med (2005) 2.62
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
TAC3/TACR3 mutations reveal preferential activation of gonadotropin-releasing hormone release by neurokinin B in neonatal life followed by reversal in adulthood. J Clin Endocrinol Metab (2010) 2.50
Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. Contraception (2009) 2.44
Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab (2004) 2.39
Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab (2004) 2.35
Geographic differences in semen quality of fertile U.S. males. Environ Health Perspect (2003) 2.30
Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med (2007) 2.27
Epidemiological study of child & adolescent psychiatric disorders in urban & rural areas of Bangalore, India. Indian J Med Res (2005) 2.15
The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact (2011) 2.15
Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab (2006) 2.08
Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care (2013) 2.07
Thrombophilic risk factors are uncommon in young patients with retinal vein occlusion. Retina (2015) 2.04
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol (2008) 1.95
Semen quality in relation to biomarkers of pesticide exposure. Environ Health Perspect (2003) 1.94
American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients--2002 update. Endocr Pract (2004) 1.69
Quality control of laboratory methods for semen evaluation in a multicenter research study. J Androl (2004) 1.64
Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care (2011) 1.60
Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery (2008) 1.58
Male pattern baldness and prostate cancer risk in a population-based case-control study. Cancer Epidemiol (2010) 1.57
GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2009) 1.55
Racial differences in vasectomy utilization in the United States: data from the national survey of family growth. Urology (2009) 1.53
The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab (2007) 1.53
Pituitary function after endonasal surgery for nonadenomatous parasellar tumors: Rathke's cleft cysts, craniopharyngiomas, and meningiomas. Surg Neurol (2008) 1.50
The Testosterone Trials: Seven coordinated trials of testosterone treatment in elderly men. Clin Trials (2014) 1.46
Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl (2007) 1.45
Serum insulin-like factor 3 is highly correlated with intratesticular testosterone in normal men with acute, experimental gonadotropin deficiency stimulated with low-dose human chorionic gonadotropin: a randomized, controlled trial. Fertil Steril (2012) 1.44
Low-fat high-fiber diet decreased serum and urine androgens in men. J Clin Endocrinol Metab (2005) 1.42
Testosterone administration decreases generosity in the ultimatum game. PLoS One (2009) 1.40
Testosterone deficiency and replacement in older men. N Engl J Med (2010) 1.39
Advances in male contraception. Endocr Rev (2008) 1.39
Clinical problem-solving. Lost in transcription. N Engl J Med (2006) 1.38
The structural basis for autonomous dimerization of the pre-T-cell antigen receptor. Nature (2010) 1.35
The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol (2008) 1.33
Genome of multidrug-resistant uropathogenic Escherichia coli strain NA114 from India. J Bacteriol (2011) 1.33
Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet (2006) 1.30
Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions. J Neurosurg (2003) 1.26
Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol (2009) 1.26
Are environmental levels of bisphenol a associated with reproductive function in fertile men? Environ Health Perspect (2010) 1.25
Testosterone administration suppresses adiponectin levels in men. J Androl (2004) 1.24
Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2007) 1.24
One semen sample or 2? Insights from a study of fertile men. J Androl (2007) 1.22
Klinefelter syndrome: expanding the phenotype and identifying new research directions. Genet Med (2003) 1.21
Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab (2005) 1.21
Computer-based order entry decreases duration of indwelling urinary catheterization in hospitalized patients. Am J Med (2003) 1.19
Serum testosterone assays--accuracy matters. J Clin Endocrinol Metab (2004) 1.19
A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl (2003) 1.19
Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab (2005) 1.19
Standardized methods for semen evaluation in a multicenter research study. J Androl (2004) 1.18
Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol (2012) 1.18
Fate of bone marrow stem cells transplanted into the testis: potential implication for men with testicular failure. Am J Pathol (2007) 1.14
Key apoptotic pathways for heat-induced programmed germ cell death in the testis. Endocrinology (2003) 1.13
A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab (2004) 1.13
Up-regulation of PPARγ, heat shock protein-27 and -72 by naringin attenuates insulin resistance, β-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. Br J Nutr (2011) 1.13
Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab (2005) 1.12
ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male (2009) 1.11
Semen quality in fertile men in relation to psychosocial stress. Fertil Steril (2009) 1.11
Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. Clin Chem (2008) 1.11
Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab (2004) 1.10
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest (2013) 1.10
Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev (2007) 1.08
Genome of a novel isolate of Paracoccus denitrificans capable of degrading N,N-dimethylformamide. J Bacteriol (2011) 1.08
Androgens and the ageing male. Best Pract Res Clin Endocrinol Metab (2004) 1.07
Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis (2006) 1.06